Staphylococcus epidermidis biofilms control by N-acetylcysteine and rifampicin

dc.contributor.authorLeite, Bruna
dc.contributor.authorGomes, Fernanda
dc.contributor.authorTeixeira, Pilar
dc.contributor.authorSouza, Clovis
dc.contributor.authorPizzolitto, Elisabeth [UNESP]
dc.contributor.authorOliveira, Rosário
dc.contributor.institutionUniversity of Minho
dc.contributor.institutionUniversidade Federal de São Carlos (UFSCar)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:29:49Z
dc.date.available2014-05-27T11:29:49Z
dc.date.issued2013-07-01
dc.description.abstractMedical device-associated infections caused by Staphylococcus epidermidis usually involve biofilm formation and its eradication is particularly challenging. Although rifampicin has been proving to be one of the most effective antibiotics against S. epidermidis biofilms, its use as a single agent can lead to the acquisition of resistance. Therefore, we assessed the combined effect of rifampicin with N-acetylcysteine (NAC) known by its mucolytic effect, in the control of S. epidermidis biofilms. Biofilms of 2 S. epidermidis strains (9142 and 1457) were treated with 1× minimum inhibitory concentration (4 mg/mL) and 10× minimum inhibitory concentration (40 mg/mL) of NAC and 10 mg/L (peak serum) of rifampicin alone and in combination. NAC at 40 mg/L alone or in combination with rifampicin (10 mg/L) significantly reduced (4 log 10) the number of biofilm cells. Considering their different modes of action, the association of NAC with rifampicin constitutes a promising therapeutic strategy in the treatment of infections associated to S. epidermidis biofilms. © 2013 Lippincott Williams & Wilkins.en
dc.description.affiliationIBB-Institute for Biotechnology and Bioengineering Centre of Biological Engineering University of Minho, Campus de Gualtar, 4710-057, Braga
dc.description.affiliationDepartment of Biotechnology Federal University of São Carlos, São Carlos
dc.description.affiliationFaculty of Pharmaceutical Sciences São Paulo State University, Araraquara
dc.description.affiliationUnespFaculty of Pharmaceutical Sciences São Paulo State University, Araraquara
dc.format.extent322-328
dc.identifierhttp://dx.doi.org/10.1097/MJT.0b013e318209e17b
dc.identifier.citationAmerican Journal of Therapeutics, v. 20, n. 4, p. 322-328, 2013.
dc.identifier.doi10.1097/MJT.0b013e318209e17b
dc.identifier.issn1075-2765
dc.identifier.issn1536-3686
dc.identifier.scopus2-s2.0-84880778397
dc.identifier.urihttp://hdl.handle.net/11449/75798
dc.identifier.wosWOS:000321982100003
dc.language.isoeng
dc.relation.ispartofAmerican Journal of Therapeutics
dc.relation.ispartofjcr1.000
dc.relation.ispartofsjr0,399
dc.relation.ispartofsjr0,399
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectBiofilm
dc.subjectN-acetylcysteine
dc.subjectPlanktonic cells
dc.subjectRifampicin
dc.subjectStaphylococcus epidermidis
dc.subjectacetylcysteine
dc.subjectmucolytic agent
dc.subjectrifampicin
dc.subjectbacterial strain
dc.subjectbiofilm
dc.subjectcontrolled study
dc.subjectdevice infection
dc.subjectdrug effect
dc.subjectminimum inhibitory concentration
dc.subjectmucolysis
dc.subjectnonhuman
dc.subjectpriority journal
dc.titleStaphylococcus epidermidis biofilms control by N-acetylcysteine and rifampicinen
dc.typeArtigo
dcterms.licensehttp://edmgr.ovid.com/spine/accounts/copyrightTransfer.pdf
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Ciências Farmacêuticas, Araraquarapt
unesp.departmentAnálises Clínicas - FCFpt

Arquivos